Nuclear transport modulators and uses thereof
View Patent ↗The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
1. A method of treating a cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia and follicular lymphoma.
2. The method of claim 1 , wherein the cancer is multiple myeloma.
3. The method of claim 1 , wherein the cancer is diffuse large B-cell lymphoma.
4. A method of treating a cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereof, wherein the cancer is colorectal cancer.
5. A method of treating a cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereof, wherein the cancer is prostate cancer.
6. A method of treating myelodysplastic syndrome, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereof.
7. A method of treating an inflammatory disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereof, wherein the inflammatory disorder is an inflammatory bowel disease.
8. The method of claim 7 , wherein the inflammatory bowel disease is selected from Crohn's disease and ulcerative colitis.
9. A method of treating nasopharyngeal cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereof.
10. The method of any one of claims 1 - 9 , wherein the compound is administered orally.